{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-018725","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.679591+00:00","generated_at":"2026-05-21T10:49:55.602169+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anteris Q1 net loss $21.9M (up 36%); sales $0.6M (-27%); DurAVR IDE submitted","bullets":["Net loss $21.9M vs $16.2M a year ago; revenue $0.6M down 27% on lower tissue demand.","R&D spend $16.5M (+42%) driven by manufacturing scale-up ($3.5M) and PARADIGM trial prep ($1.5M).","Cash at March 31: $49.0M; IPO green-shoe raised $0.47M; included in Russell 2000.","DurAVR THV IDE for pivotal PARADIGM Trial submitted to FDA; 100+ patients treated; one-year data shows EOA 2.1 cm², MPG 8.6 mmHg, no valve mortality.","Manufacturing capacity scaled to 3x 2024 levels; ADAPT tissue sourced from US and Australia to mitigate supply risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-018725","json":"https://secwatch.observer/filing/0001140361-25-018725.json","markdown":"https://secwatch.observer/filing/0001140361-25-018725.md","text":"https://secwatch.observer/filing/0001140361-25-018725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125018725/0001140361-25-018725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125018725/ef20048845_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:49:55.602169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}